EFFECTS OF MENATETRENONE ON PREDNISOLONE-INDUCED BONE LOSS IN RATS

被引:70
作者
HARA, K
AKIYAMA, Y
OHKAWA, I
TAJIMA, T
机构
[1] Pharmacological Evaluation Section, Department of Drug Research II, Eisai Co., Ltd., Tokyo
关键词
MENATETRENONE; PREDNISOLONE; BONE LOSS; RATS; URINARY GLA CONTENT; PLASMA NORMAL PROTHROMBIN;
D O I
10.1016/8756-3282(93)90309-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study was carried out to evaluate the effect of menatetrenone, a vitamin K2 with 4 isoprene units, on prednisolone-induced bone loss. Three experiments were performed in rats which received menatetrenone as a dietary supplement. In experiment 1, a soluble form of prednisolone, dissolved in drinking water, was administered to rats at 7 mg/kg/day for 9 weeks. The length, dry weight, and bone density of femurs and tibiae, as well as urinary gamma-carboxyglutamic acid (Gla) content, were significantly lower in the prednisolone-control group than in the intact group. Menatetrenone (17 mg/kg/day) significantly inhibited the decrease in these bone parameters, especially in tibiae, and completely inhibited the decrease in urinary Gla content. In experiments 2 and 3, prednisolone (10 mg/kg), dissolved in cottonseed oil, was given to rats intramuscularly three times a week for 4 and 10 weeks. respectively. In experiment 2, bone length, bone strength and calcium content in the femur were reduced by 4-week prednisolone treatment. These reductions were significantly improved by menatetrenone (21 mg/kg/day). In experiment 3, 10-week prednisolone treatment reduced bone length and the calcium and hydroxyproline content of the femur. Menatetrenone (0.4, 10, and 50 mg/kg/day) significantly inhibited the reduction of calcium content in the femur. These results suggest that menatetrenone may inhibit the bone loss induced by corticosteroid treatment.
引用
收藏
页码:813 / 818
页数:6
相关论文
共 33 条
[1]   EFFECTS OF MENATETRENONE ON BONE LOSS INDUCED BY OVARIECTOMY IN RATS [J].
AKIYAMA, Y ;
HARA, K ;
OHKAWA, I ;
TAJIMA, T .
JAPANESE JOURNAL OF PHARMACOLOGY, 1993, 62 (02) :145-153
[2]   HISTOMORPHOMETRIC PROFILE, PATHOPHYSIOLOGY AND REVERSIBILITY OF CORTICOSTEROID-INDUCED OSTEOPOROSIS [J].
BRESSOT, C ;
MEUNIER, PJ ;
CHAPUY, MC ;
LEJEUNE, E ;
EDOUARD, C ;
DARBY, AJ .
METABOLIC BONE DISEASE & RELATED RESEARCH, 1979, 1 (04) :303-311
[3]   ISOLATION OF THE HUMAN-GENE FOR BONE GLA PROTEIN UTILIZING MOUSE AND RAT CDNA CLONES [J].
CELESTE, AJ ;
ROSEN, V ;
BUECKER, JL ;
KRIZ, R ;
WANG, EA ;
WOZNEY, JM .
EMBO JOURNAL, 1986, 5 (08) :1885-1890
[4]  
DELMAS PD, 1990, ENDOCRIN METAB CLIN, V19, P1
[5]  
GENNARI C, 1985, BONE MINERAL RES ANN, V3, P213
[6]   EFFECTS OF SHORT-TERM GLUCOCORTICOID ADMINISTRATION ON INTESTINAL CALCIUM-ABSORPTION AND CIRCULATING VITAMIN-D METABOLITE CONCENTRATIONS IN MAN [J].
HAHN, TJ ;
HALSTEAD, LR ;
BARAN, DT .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1981, 52 (01) :111-115
[7]   ALTERED MINERAL METABOLISM IN GLUCOCORTICOID-INDUCED OSTEOPENIA - EFFECT OF 25-HYDROXYVITAMIN-D ADMINISTRATION [J].
HAHN, TJ ;
HALSTEAD, LR ;
TEITELBAUM, SL ;
HAHN, BH .
JOURNAL OF CLINICAL INVESTIGATION, 1979, 64 (02) :655-665
[8]   MATERNAL AND FETAL SEQUELAE OF ANTICOAGULATION DURING PREGNANCY [J].
HALL, JG ;
PAULI, RM ;
WILSON, KM .
AMERICAN JOURNAL OF MEDICINE, 1980, 68 (01) :122-140
[9]  
HARA K, 1993, J BONE MINER RES, V8, P535
[10]   ELECTROCHEMICAL DETECTION OF DEPRESSED CIRCULATING LEVELS OF VITAMIN-K1 IN OSTEOPOROSIS [J].
HART, JP ;
SHEARER, MJ ;
KLENERMAN, L ;
CATTERALL, A ;
REEVE, J ;
SAMBROOK, PN ;
DODDS, RA ;
BITENSKY, L ;
CHAYEN, J .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1985, 60 (06) :1268-1269